Immunex Corp. and Wyeth’s pharmaceuticals unit said Enbrel was effective in treating moderate to severe plaque psoriasis, according to a Phase II study.
Enbrel, a fully human soluble receptor, has already demonstrated efficacy in treating patients with moderately to severely active rheumatoid arthritis.
PBN Branded Content
Rhode Island's Market Has Changed. Developers, Builders, Investors and Sellers Must Change With It.
By Emilio DiSpirito IV License Partner | Engel & Völkers Oceanside Leader | The DiSpirito…
Learn More
In a press release Wednesday, Immunex said 53% of psoriasis patients treated with Enbrel were clear or almost clear of skin lesions at 6 months, compared to 5% of patients treated with placebo.
The companies also began a second, global Phase III pivotal study assessing the efficacy and tolerability of Enbrel to treat moderate to severe plaque psoriasis.
- Advertisement -
